Amneal Pharmaceuticals (AMRX) Accumulated Expenses (2018 - 2026)

Amneal Pharmaceuticals' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 75.75% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $10.5 million, a 75.75% decrease from a year earlier, with the FY2025 full-year figure at $43.3 million, up 36.22% from the prior year.
• Accumulated Expenses fell to $10.5 million in Q1 2026 per AMRX's latest filing, from $43.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $275.3 million in Q2 2022 and bottomed at $10.5 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $43.4 million (2025), against an average of $73.0 million.
• Across the five-year window, Accumulated Expenses jumped 85.32% in 2022 and tumbled 75.75% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $107.5 million in 2022, then dropped by 28.37% to $77.0 million in 2023, then plunged by 58.75% to $31.8 million in 2024, then jumped by 36.22% to $43.3 million in 2025, then plunged by 75.61% to $10.5 million in 2026.
• Per Business Quant, the three latest AMRX Accumulated Expenses figures stand at $10.5 million (Q1 2026), $43.3 million (Q4 2025), and $40.6 million (Q3 2025).